ASX-Dividend-Report-Banner

Qiming's Nisa Leung Made the 2024 Forbes Midas List

June 05, 2024 02:01 AM AEST | By Cision
 Qiming's Nisa Leung Made the 2024 Forbes Midas List
Image source: Kalkine Media

SHANGHAI, June 4, 2024 /PRNewswire/ -- The 2024 Forbes Midas List, a distinguished industry list of the world's best venture capital investors, has been unveiled. Nisa Leung, Managing Partner at Qiming Venture Partners, has become a Forbes Midas Lister for the sixth consecutive year, ranking 40th this year.

The Forbes Midas List celebrates honorees' extraordinary investment insights and accomplishments.

Nisa and her team have shown a strong commitment to identifying startups that enhance the healthcare system while addressing global unmet medical needs. Over the past decade, Nisa and her team have overseen over 220 healthcare companies, including Gan & Lee Pharmaceuticals (SHSE:603087), SinocellTech (SHSE:688520), Structure Therapeutics (NASDAQ: GPCR), Zai Lab (NASDAQ:ZLAB, SEHK:9688), Schrödinger (NASDAQ:SDGR), Belief BioMed, and Caidya.

This award recognizes Nisa's professional skills while also serving as a testament to the innovative investment strategies and sector expertise of Qiming. Qiming now manages eleven US dollar funds and seven RMB funds, totaling $9.5 billion in capital raised. Since its inception, Qiming has invested in outstanding companies in the Healthcare and Technology and Consumer (T&C) industries at the early and growth stages. In 2023, Qiming strategically and methodically invested in nearly 80 companies in the sectors.

Qiming has maintained a steady investment pace in 2023 and continued to evaluate and invest in exciting and disruptive areas. Additionally, Qiming strategically participated follow-on investments in high-quality portfolio companies.

Meanwhile, Qiming strengthened its post-investment ecosystem of support services, including events, recruitments, market communication, research, financial advisory and business development. These services aim to bolster support to entrepreneurs and portfolio companies.

About Qiming Venture Partners

Qiming Venture Partners was founded in 2006. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.

Since our debut, we have backed over 530 fast-growing and innovative companies. Over 200 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 70 portfolio companies that have achieved unicorn or super unicorn status.

Many of our portfolio companies are today's most influential firms in their respective sectors, including Xiaomi (SEHK:1810), Meituan (SEHK:3690), Bilibili (NASDAQ:BILI, SEHK:9626), Zhihu (NYSE:ZH, SEHK:2390), Roborock (SHSE:688169), Gan & Lee Pharmaceuticals (SHSE:603087), Tigermed (SZSE:300347, SEHK:3347), Zai Lab (NASDAQ:ZLAB, SEHK:9688), CanSino Biologics (SEHK:6185, SHSE:688185), Schrödinger (NASDAQ:SDGR), APT Medical (SHSE:688617), New Horizon Health (SEHK:6606), Sanyou Medical (SHSE:688085), AmoyDx (SZSE:300685), Berry Genomics (SZSE:000710), SinocellTech (SHSE:688520), UBTech (SEHK:9880), Yuanxin Technology, Caidya, Belief BioMed, WeRide, among many others.

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.